Memorial Sloan Kettering Cancer Center: Carcinoma, Squamous Cell trials

The registry lists 19 Carcinoma, Squamous Cell studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 2 are open to participants now and 5 have results posted.

Phase 1 7Phase 2 6No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor CancerRecruitingNCT05859074Phase 1
• Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With PathologyRecruitingNCT02507141
• Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT02684253Phase 2Results posted
• Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell CarcinomaCompletedNCT01268579Not applicableResults posted
• Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)CompletedNCT01183065Phase 2Results posted
• Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)CompletedNCT01016769Phase 1/2Results posted
• Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell CancerCompletedNCT00661427Phase 2Results posted
• A Study of Radiation Therapy and Cemiplimab for People With Skin CancerActive, not recruitingNCT05574101Phase 2
• Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of DiseaseActive, not recruitingNCT05048459Not applicable
• Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CancerCompletedNCT03667482Phase 1
• Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell CarcinomaCompletedNCT03524326Phase 1
• Validation of a Health-Related Symptom Index for Persons Diagnosed With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL)CompletedNCT02836522
• Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)CompletedNCT02282371Phase 1
• Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell CarcinomaCompletedNCT02131805Not applicable
• Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)CompletedNCT01721525Phase 1
• Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell CarcinomaCompletedNCT00968435Phase 2
• Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedNCT00736619Phase 1
• Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell CarcinomaCompletedNCT00620139
• Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell CarcinomaCompletedNCT00596219Not applicable